

One Voice Against Cancer Appropriations Requests

FY 2023 OVAC Appropriations Request

(all \$ in millions)

<u>Program</u>	<u>FY21</u>	<u>FY22</u>	<u>FY23</u>			<u>OVAC Request</u>
	<u>Enacted</u>	<u>Enacted</u>	<u>President's Request</u>	<u>House Bill</u>	<u>Senate Bill</u>	
Cancer Research						
Base funding for National Institutes of Health (Labor-HHS Appropriations) ¹	\$42,934	\$44,959	\$45,233	\$47,459	\$46,959	\$49,048
National Cancer Institute ²	\$6,560	\$6,913	\$6,714	\$7,379	\$7,203	\$7,766
National Institute on Minority Health and Health Disparities	\$391	\$459	\$660	\$505	\$534	\$660
National Institute on Nursing Research	\$175	\$181	\$199	\$209	\$196.5	\$199
Advanced Research Projects Agency for Health (ARPA-H) ³	\$0	\$1,000	\$5,000	\$2,750	\$1,000	TBD ⁴
Cancer Prevention and Control						
Centers for Disease Control Cancer Prevention and Control Programs	\$385.8	\$389.8	\$430.8	\$429.5	\$420	\$462.6
Comprehensive Cancer Control Initiative	\$20.4	\$20.4	\$30.2	\$26.4	\$30.4	\$30.2
Cancer Registries	\$51.4	\$51.4	\$61.4	\$56.4	\$56.4	\$61.4
National Breast & Cervical Cancer Early Detection Program (incl. Wisewoman)	\$225	\$227	\$240	\$244.5	\$240	\$258
National Breast & Cervical Cancer Early Detection Program (cancer only) ⁵	\$196.9	\$196.9	\$211.9	\$206.9	\$206.9	\$225
Colorectal Cancer	\$43.3	\$43.3	\$48.3	\$45.3	\$43.3	\$50
Skin Cancer	\$4	\$4	\$5	\$5	\$5	\$5
Prostate Cancer	\$14.2	\$14.2	\$16.2	\$15.2	\$15.2	\$20
Ovarian Cancer	\$12	\$12.5	\$12	\$14.5	\$12.5	\$15
Johanna's Law	\$10	\$10.5	\$11	\$12.5	\$10.5	\$15
Cancer Survivorship	\$0.475	\$0.475	\$0.725	\$0.725	\$0.725	\$1
Breast Cancer Awareness for Young Women	\$4.96	\$5.96	\$5.96	\$8.96	\$5.96	\$7
Investing in Regulatory Programs to Improve the Pipeline of Delivery						
Food and Drug Administration (excluding user fees)	\$3,215	\$3,317	\$3,673	\$3,662	\$3,545	TBD

NOTE 1: Levels in this row do not include funding for ARPA-H.

NOTE 2: Includes funding provided through the 21st Century Cures Act. The amount in FY21 is \$195 million; in FY22, \$194 million; in FY23, \$216 million.

NOTE 3: The House bill and the Senate Democratic bill take different approaches to ARPA-H's structure and the overall NIH funding level. The Senate Democratic bill assumes that ARPA-H will be housed within NIH, so the bill's NIH total (\$47.959 billion) includes \$1 billion for ARPA-H on top of the NIH base funding. The House bill assumes that ARPA-H will be housed outside of NIH, so the bill's NIH total (\$47.459 billion) does not include ARPA-H funding.

NOTE 4: OVAC supports ARPA-H but did not recommend an amount for FY23.

NOTE 5: Amount does not include the Wisewoman heart disease program, which is housed within the breast and cervical cancer program. Within the total for this program, OVAC requests at least \$225 million for non-Wisewoman activities.